TITLE:  Lyophilized Plasma for the Treatment of Adults with Hemorrhagic Shock: Clinical and Cost-Effectiveness, Safety, and Guidelines

DATE:  18 February 2014

RESEARCH QUESTIONS

1. What is the clinical effectiveness of lyophilized plasma for treating adults with hemorrhagic shock?

2. What is the safety of using lyophilized plasma for treating adults with hemorrhagic shock?

3. What is the cost-effectiveness of using lyophilized plasma for treating adults with hemorrhagic shock?

4. What are the guidelines associated with the use of lyophilized plasma for treating adults with hemorrhagic shock?

KEY MESSAGE

No relevant literature was identified regarding lyophilized plasma for treating adults with hemorrhagic shock.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 1), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. The search was limited to English and French language documents published between January 1, 2009 and February 4 2014. Internet links were provided, where available.

The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article.

Disclaimer:  The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright:  This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links:  This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
RESULTS

No relevant health technology assessments, systematics review, meta-analyses, randomized controlled trials, non-randomized studies, economic evaluations, or evidence-based guidelines were identified regarding lyophilized plasma for treating adults with hemorrhagic shock.

References of potential interest are provided in the appendix.

OVERALL SUMMARY OF FINDINGS

No relevant literature was found regarding lyophilized plasma for treating adults with hemorrhagic shock was identified, therefore no summary can be provided.
REFERENCES SUMMARIZED

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses
No literature identified.

Randomized Controlled Trials
No literature identified.

Non-Randomized Studies
No literature identified.

Economic Evaluations
No literature identified.

Guidelines and Recommendations
No literature identified.

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Non-Randomized Studies – Retrospective Descriptive Study

transfusion on battlefield. The Kabul hospital experience]. Ann Fr Anesth Reanim. 2013

Review Articles

2. Godier A, Samama CM, Susen S. Plasma/platelets/red blood cell ratio in the management


Additional References

5. Bux J, Dickhorner D, Scheel E. Quality of freeze-dried (lyophilized) quarantined single-

Point-of-injury use of reconstituted freeze dried plasma as a resuscitative fluid: a special
report for prehospital trauma care. J Trauma Acute Care Surg. 2013 Aug;75(2 Suppl

Freeze-dried plasma at the point of injury: from concept to doctrine. Shock. 2013

8. Hess JR, Lelkens CC, Holcomb JB, Scalea TM. Advances in military, field, and austere
PubMed: PM23856530


